- |||||||||| ivabradine / Generic mfg.
Review, Journal: Ivabradine in Septic Shock: A Narrative Review. (Pubmed Central) - Apr 27, 2024
By exerting a selective chronotropic effect devoid of negative inotropic properties, ivabradine shows potential for improving hemodynamics in septic shock patients with cardiac dysfunction. This review evaluates the plausible mechanisms and existing evidence regarding the utility of ivabradine in managing patients with septic shock.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
Journal: Evaluation of Stages, Treatment Protocols, and Outcomes of Colorectal Cancer among West Bank Patients. (Pubmed Central) - Apr 27, 2024
More studies need to be undertaken to investigate the actual application of chemotherapy protocols, and survival would benefit from the involvement of clinical pharmacists in the chemotherapy protocol selection, dosing, frequency, and follow-up. The present study advocates for greater public awareness of CRC and attests to the merits of screening by primary care professionals, which can help to avoid this serious illness and to promote a better prognosis.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Review, Journal: T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies. (Pubmed Central) - Apr 27, 2024
In 2014, the FDA approved blinatumomab, a TCE directed to CD3 and CD19 for treatment of acute lymphoblastic leukemia...TCE-based therapies still have their limitations; however, improving the properties of TCEs, as well as combining TCE-based therapies with other forms of treatment, give hope to find the cures for currently terminal diseases. In this paper, we summarized the technical basis of the TCE technology, its application in hematology, and its current issues and prospects.
- |||||||||| Kepivance (palifermin) / SOBI, Amgen
Review, Journal: Oral Mucositis Management in Children under Cancer Treatment: A Systematic Review. (Pubmed Central) - Apr 27, 2024
Low-level laser therapy, palifermin, honey, and zinc demonstrated reductions in oral mucositis incidence, duration, severity, and pain reported by the patient. Although there are several therapies in place for the prevention and treatment of oral mucositis in children, evidence of their efficacy is still inconclusive to establish accurate clinical protocols.
- |||||||||| Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Preclinical, Review, Journal: Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer. (Pubmed Central) - Apr 27, 2024
In this review, we summarize the biology of the KRAS protein and the characteristics of KRAS mutations. We then present current and emerging therapeutic approaches for targeting KRAS mutation subtypes intending to provide individualized treatment for lung cancer harboring this challenging driver mutation.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Clinical, Observational data, Retrospective data, Journal, Real-world evidence, Real-world effectiveness, Real-world: Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study. (Pubmed Central) - Apr 26, 2024
In this exploratory analysis, anti-CGRP mAbs showed superior effectiveness for HIT-6 and ASC12 compared to BoNT-A. Reductions in terms of month headache days (MHD), migraine disability assessment test (MIDAS), and migraine acute medications (MAM) were clinically relevant for both treatments.
- |||||||||| Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
Clinical data, Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data. (Pubmed Central) - Apr 26, 2024
The two-year overall survival (95% CI) was 97.4% (92.4, 100.0), and the median (range) follow-up was 28.7 (3.4-67.6) months. Despite the limitations inherent in real-world studies and a limited number of patients, these AI-extracted data complement previous studies, demonstrating the effectiveness of CDK4/6i + ET in the Canadian real-world 1L, with most patients receiving palbociclib as CDK4/6i in 1L.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer
Review, Journal, HEOR, Metastases: Impact of Systemic Treatments on Outcomes and Quality of Life in Patients with RAS-Positive Stage IV Colorectal Cancer: A Systematic Review. (Pubmed Central) - Apr 26, 2024
Surgery is the mainstay treatment for malignant GCTB. From an initial pool of 1345 articles, 11 relevant studies were selected for inclusion, encompassing a diverse range of systemic treatments, including panitumumab combined with FOLFOX4 and FOLFIRI, irinotecan paired with panitumumab, regorafenib followed by cetuximab
- |||||||||| Review, Journal: Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions. (Pubmed Central) - Apr 26, 2024
However, monoclonal antibodies may worsen diseases with already weakened CGRP neurotransmission, Raynaud phenomenon and constipation. Monoclonal antibodies used for prevention of migraine do not engage in significant pharmacokinetic interactions with other drugs; however, they do engage in pharmacodynamic interactions with other anti-migraine drugs, additively augmenting their prophylactic action, but also increasing frequency and severity of adverse reactions, which are a consequence of the CGRP neurotransmission interruption.
- |||||||||| Review, Journal, Immunomodulating: Novel immunomodulatory therapies in myasthenia gravis (Pubmed Central) - Apr 26, 2024
This review explores new immunosuppressive therapies and ongoing clinical trials in MG, including depletion of B lymphocytes with agents such as rituximab and inebilizumab, as well as the use of eculizumab, efgartigimod, satralizumab, tocilizumab, and CAR-T (Chimeric Antigen Receptor-T) cell therapy. These advancements aim to improve disease control and patients' quality of life.
- |||||||||| Ibrance (palbociclib) / Pfizer
Journal: Differential synergistic effects of palbociclib and doxorubicin on doxorubicin-resistant cancer cells with diverse tumor origins. (Pubmed Central) - Apr 26, 2024
As a monotherapy, palbociclib has been shown to decrease the expression of MDR-1 in doxorubicin-resistant cells, and when used in combination with doxorubicin, it has been shown to increase the accumulation of doxorubicin in the cell and consequently induce apoptosis. This is the first report that proposes the Palbociclib as a candidate for combination therapy to limit the Doxorubicin resistance in different cancer origins in clinics.
- |||||||||| Trial completion date, Trial primary completion date: KOBIO: Korean College of Rheumatology Biologics and Targeted Therapy Registry (clinicaltrials.gov) - Apr 26, 2024
P=N/A, N=10000, Recruiting,
This is the first report that proposes the Palbociclib as a candidate for combination therapy to limit the Doxorubicin resistance in different cancer origins in clinics. Trial completion date: Jun 2025 --> Jun 2030 | Trial primary completion date: Dec 2024 --> Dec 2029
- |||||||||| Boyoubei (denosumab biosimilar) / Luye Group
Enrollment closed: Comparative Efficacy, Safety, PK, and Immunogenicity Study (clinicaltrials.gov) - Apr 26, 2024
P3, N=392, Active, not recruiting,
Trial completion date: Jun 2025 --> Jun 2030 | Trial primary completion date: Dec 2024 --> Dec 2029 Recruiting --> Active, not recruiting
- |||||||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
Review, Journal: SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. (Pubmed Central) - Apr 25, 2024
Achieving NGS MRD negativity can also identify patients who may have durable remissions with a low risk of relapse. Herein, we discuss the current approach to the management of adults with Ph-positive ALL, the role of HSCT, MRD monitoring, and future therapies.
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
Retrospective data, Review, Journal: The incidence of uveitis in patients with axial spondylarthritis treated with biologics or targeted synthetics: a systematic review and network meta-analysis. (Pubmed Central) - Apr 25, 2024
Herein, we discuss the current approach to the management of adults with Ph-positive ALL, the role of HSCT, MRD monitoring, and future therapies. Anti-TNF mAbs, JAKi, and anti-IL-17 appear protective against AU events in individuals with AxSpA, with no significant differences in risk of AU between treatments.
- |||||||||| spartalizumab (PDR001) / Novartis
Biomarker, P1/2 data, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Stroma, Metastases: Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 plus Imatinib for Advanced Treatment-refractory Gastrointestinal Stromal Tumors. (Pubmed Central) - Apr 25, 2024
Based on the perceived response to filgrastim in this single feline case report, its use can be considered for the treatment of azathioprine-induced neutropenia in cats. In patients with treatment-refractory GIST, PDR001 in combination with imatinib was generally tolerable, but it was not effective.
- |||||||||| Repatha (evolocumab) / Amgen, Astellas
Trial completion date, Trial primary completion date: EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction (clinicaltrials.gov) - Apr 25, 2024
P4, N=6000, Recruiting,
Recruiting --> Suspended Trial completion date: Nov 2027 --> May 2027 | Trial primary completion date: Nov 2027 --> May 2027
- |||||||||| Prolia (denosumab) / Amgen
Trial termination, Metastases: SPLENDOUR: Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (clinicaltrials.gov) - Apr 25, 2024
P3, N=595, Terminated,
Completed --> Terminated; Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a benefit for denosumab could be shown, these results would be of very limited clinical impact by the time they would be available
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Changes in Testing and Treatment Methods in Osteoporosis Care. (Pubmed Central) - Apr 25, 2024
Regarding therapeutic agents, bisphosphonates decreased in usage, whereas parathyroid hormone and romosozumab witnessed an increase...In addition, more physicians chose to utilise bone metabolic markers due to their ease of measurement through blood tests and reduced diurnal variation. Finally, there was a marked trend towards the administration of drugs capable of rapidly and effectively increasing bone mineral density at an early stage of treatment.
- |||||||||| Zepsun (donafenib) / Suzhou Zelgen, Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Comparative efficacy of systemic sequential regorafenib after TACE combined with first-line targeted drugs (donafenib, sorafenib, or lenvatinib) after treatment failure for advanced hepatocellular carcinoma: A retrospective, single-center, real-world study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6910;
This retrospective, single-center, real-world study demonstrated that when donafenib failed the regorafenib could still improve the prognosis of advanced HCC pts with fewer AEs. The study will continue to focus on overall survival(OS) and whether combined ICIs or not in the 1st-line/ 2nd-line treatment could have a positive effect on OS.
- |||||||||| Prolia (denosumab) / Amgen
Place of Rank ligand inhibitor in giant cell tumour of bone. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6801;
The treatment is essentially surgical. Denosumab is indicated for both neoadjuvant and adjuvant use, it allows obtaining a clear clinical and radiological improvement.
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
The analysis of prescribing CDK4/6 inhibitors for patients with breast cancer in real clinical practice. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6786;
The analysis showed that Ribociclib is more often prescribed in the 1 line for patients with a higher 'tumor burden' and with primary hormone resistance. In relation to this, we observe a decrease in such an indicator as the frequency of overall response in this group of patients compared to Palbociclib.
- |||||||||| Imlygic (talimogene laherparepvec) / Amgen, Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Opdivo (nivolumab) / BMS
An update on SOC-1882: A phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6718;
P2
Taken together, the data confirms our previous report that (1) the combination regimen using Talimogene laherparepvec, Nivolumab & Trabectedin may be more effective and treatment for previously treated patients with advanced leiomyosarcoma with manageable toxicity, and (2) The best responders are patients with HR+ uterine LMS. Clinical trial information: NCT03886311.
- |||||||||| Stivarga (regorafenib) / Bayer
A phase 2 study of regorafenib in metastatic/unresectable, refractory synovial sarcomas. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6563;
Regorafenib in the above-mentioned dosing regimen demonstrated meaningful clinical activity in a heavily pre-treated population of patients with synovial sarcoma, including those previously exposed to pazopanib, with a preserved quality of life. The treatment was associated with manageable toxicities and no new safety signals, albeit with higher HFSR rates.
|
